Designing a Simulation Study for Trial Planning

Why Plan the Simulation Before Running It?

A simulation study is useful only when it answers a defined design question. A large number of simulated trials cannot compensate for unclear targets, unrealistic assumptions, or an analysis procedure that differs from the one intended for the actual trial. Planning therefore begins by stating what trial outcomes matter and under which possible conditions the design will be assessed.

For a group sequential trial, the plan must connect the full sequence of planned analyses to the final design decision. It should identify the scenarios to simulate, the estimands to summarize, the analysis and stopping rules applied to each hypothetical trial, and the criteria for deciding whether a design is acceptable. The purpose here is to specify that study coherently; detailed trial-path generation and Monte Carlo precision are separate implementation questions.

Specify the Design and the Data-Generating Scenarios

First describe the design to be evaluated. State the maximum number of analyses, their planned information times, the efficacy and futility rules, the maximum information or sample size, and any adaptations that are part of the design. Use consistent indices: let \(k=1,\ldots,K\) index the planned looks, and let \(t_k\) denote the information fraction at look \(k\), with \(0<t_1<\cdots<t_K=1\). These values describe when analyses are planned, not what result they will produce.

Next specify the data-generating scenarios. A scenario gives the assumptions that determine the data in a hypothetical trial, including the treatment effect and relevant nuisance or operational features. For example, scenarios might differ in the true effect, control event rate, outcome variability, accrual pattern, or amount of missing outcome data. Include conditions that could materially change the trial’s operating characteristics, rather than varying every conceivable input.

A standard starting point for a group sequential design with a continuous score is the canonical information model. If \(Z_k\) is the standardized test statistic at look \(k\), \(I_k\) is the information at that look, and \(\theta\) is the effect per square root of information, the model can be written

where \(B(I)\) is a standard Brownian motion. Under this model, increments in \(B(I)\) over nonoverlapping information intervals are independent, and the covariance structure across looks follows from the shared accumulated information. Under \(H_0\), \(\theta=0\); an alternative scenario specifies a nonzero effect. This model is an assumption, not a universal description of trial data. If the planned analysis or data structure makes it unsuitable, use a data-generating model that represents that structure and apply the intended analysis to the generated data.

Define the Analysis, Stopping Outcomes, and Performance Measures

The simulated trials must be analyzed as the real trial would be analyzed. Specify the test statistic, variance or standard-error calculation, treatment of missing outcomes, and any adjustment used for interim analyses. Then state the stopping rules precisely: which boundary crossing counts as efficacy stopping, whether a futility rule is binding or nonbinding, what happens when neither rule triggers, and how the final analysis is handled. If the intended trial includes a sample-size adaptation, describe that rule as part of the analysis procedure rather than as an informal response to simulated results.

Choose performance measures that directly answer the planning question. A measure should have a clear event or quantity, a scenario to which it applies, and, where relevant, units. Typical choices include the probability of rejecting \(H_0\) under the null, the probability of rejecting \(H_0\) under a specified alternative, the probability of efficacy or futility stopping at each look, expected total information or sample size, and the probability of reaching the maximum sample size. These measures are not interchangeable: for example, overall rejection probability does not tell the team at which look rejection usually occurs.

For a binary event, the rationale for the corresponding simulation summary is direct. Let \(Y_r\) equal 1 if replicate \(r\) has the event of interest and 0 otherwise. If \(Y_r\) follows the same scenario and analysis procedure on each independently generated replicate, then \(E(Y_r)\) is the event probability. The average of the replicate indicators targets that probability:

The equality follows from linearity of expectation. For a numerical outcome such as total sample size \(N_r\), the corresponding estimand may be \(E(N_r)\), the expected sample size under the specified scenario. These definitions clarify what the simulation is intended to summarize; they do not, by themselves, establish that the number of replicates is adequate for the desired precision.

Set Decision Criteria and Choose Scenario Weights Carefully

A useful plan says in advance how the performance measures will affect the design decision. For instance, the design might need to meet a prespecified upper limit on false rejection under the null and a minimum power target at the clinically relevant effect. It may also need to keep expected sample size or the chance of reaching maximum enrollment below an operational limit. These requirements should reflect the trial’s scientific and operational objectives, not be selected after seeing favorable results.

Usually, report scenario-specific results first. A weighted average across scenarios is meaningful only when the weights have an explicit interpretation, such as a justified distribution over plausible conditions for a decision focused on average performance. If the question is robustness to a range of effects or nuisance values, a single average can conceal poor performance in an important scenario. Report the range or the relevant worst-case result as well.

Justification, Diagnostics, and Alternatives

The planning logic can be summarized as a chain of definitions. A scenario determines a probability distribution for trial data. The analysis and stopping rules map those data to an outcome, such as rejection or total sample size. Applying a prespecified summary to that outcome defines an estimand. Therefore, changing any link can change the estimand itself. This is why a simulation plan must lock down the scenario, analysis, stopping outcome, and summary before comparing candidate designs.

Check the plan for failure modes before it is run. An event such as “stopping early” is incomplete unless it distinguishes efficacy from futility and identifies the relevant looks. Scenarios that omit plausible control rates, variability, or missingness can make conclusions overly dependent on optimistic assumptions. A mismatch between the simulated data and the analysis model can evaluate a different procedure from the one intended for the trial. Finally, an undocumented scenario weight or a decision threshold chosen after results are seen makes the conclusion difficult to interpret.

Analytic group sequential calculations are often the more efficient alternative when their assumptions match the design and the required operating characteristics are available from standard methods. Simulation is particularly useful when the planned analysis, outcome generation, nuisance estimation, missingness, or adaptation is too complicated for a trusted analytic calculation. Simulation is not automatically more reliable: it inherits its assumptions from the data-generating model and its conclusions depend on correct implementation.

A simulation study also has limits. It assesses only the scenarios and performance measures it includes; it cannot prove good performance under every possible future condition. A finite set of scenarios is a planned examination of uncertainty, not a guarantee that all relevant uncertainty has been captured. Keep the estimands, scenarios, analysis rules, and decision criteria documented so that results can be interpreted against the questions they were designed to answer.